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Abstract 
Background: Improvement in acromegaly management increased disease survival and prevalence. Evidence regard-
ing acromegaly in older adults are sparse. We aim to explore acromegaly impact on aging process quality.
Methods: Multicenter case-control study conducted on 42 older adults (≥ 65 years) acromegaly patients (ACRO) 
compared to an age- and gender-matched control group (CTR). Each participant underwent a multidimensional 
geriatric evaluation.
Results: Mean age in both groups was 73 ± 6 years and female gender was most represented (69%). All comorbidi-
ties were more frequent in ACRO than CTR. Thirteen ACRO were in remission and 29 had active disease controlled by 
medical therapy except for one patient. ACRO showed worse physical performance and mobility skills worsening with 
age as compared to CTR. ACRO performed poorly in functional status assessment, and age negatively correlated with 
instrumental and basic daily activities execution. Cognitive evaluation scores were significantly lower in ACRO vs. CTR, 
worsening with age. No difference was found concerning nutritional and psychological status. Musculoskeletal and 
bone diseases were more frequent in ACRO than in CTR (52% vs. 12%; 64% vs. 10%; P < 0.05) and independently asso-
ciated with geriatric outcomes in ACRO. ACRO reported a less satisfactory quality of life concerning physical activity 
and pain, general health, vitality, social activities.
Conclusions: Our study demonstrates increased frailty of older acromegaly patients as compared to non-acromegaly 
patients with a consequent negative impact on their quality of life. Therefore, it seems advisable to include physical, 
functional, cognitive, nutritional, and psychological status assessments in routine clinical practice. Further studies are 
needed to identify the most appropriate geriatric tools.
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Background
Acromegaly is a rare disease caused by growth hormone 
(GH) hypersecretion mostly due to a pituitary adenoma, 
with consequent increase in insulin-like growth factor-1 
(IGF-1) levels. Acromegaly presents with a progres-
sive and chronic systemic involvement and comorbidi-
ties (cardiovascular, respiratory, metabolic, neoplastic, 
neurological, musculoskeletal) that are responsible for 
increased morbidity and mortality [1]. Literature reports 
a higher risk to develop cognitive impairment [2–6], 
psychopathologies [7–14], poor physical and func-
tional performance [2, 15, 16] with negative effects on 
global quality of life (QoL). Improvement in diagnostic 
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approaches, surgical techniques, medical therapies over 
the years has increased acromegaly survival and preva-
lence in all age groups [17–21]. Recent epidemiological 
data suggest a reduction in acromegaly mortality with 
death causes more similar to those of the general popula-
tion of corresponding age. Therefore, the number of older 
patients with acromegaly, newly diagnosed or in follow-
up, is expected to grow in the coming years. At the same 
time, the general population’s life span increased [18–24]. 
We recently reviewed data from the literature to define 
acromegaly characteristics in the elderly but data regard-
ing the impact of acromegaly disease on the natural aging 
course are still sparse [17]. Hatipoglu et  al. have under-
lined the importance of a geriatric multidimensional 
assessment also in older patients with acromegaly since 
the disease may enhance some aspects of the aging pro-
cess (cognitive dysfunction, malnutrition risk, reduced 
physical performance, mood impairment) [2].
In this multicenter study we aim to define how acro-
megaly can impact on the quality of the aging process as 
compared to older general population. To this purpose, 
we performed a multidimensional evaluation of a cohort 
of Italian older acromegaly patients to assess their clini-
cal, cognitive, functional, nutritional, and psychological 
status as compared to non-acromegaly older subjects.
Methods
This multicenter case-control study was conducted in two 
Italian endocrinological centers (Azienda Ospedaliero 
Universitaria of Ferrara and Policlinico A. Gemelli of 
Rome). Older acromegaly patients were recruited among 
those patients aged ≥65 years old. Acromegaly diagnosis 
was based on: 1) the presence of typical clinical features, 
2) IGF-1 levels higher than age and sex adjusted reference 
ranges, 3) an abnormal GH response to an oral glucose 
tolerance test, 4) the presence of a pituitary adenoma. 
Study population included 42 cases (ACRO). The con-
trol group (CTR) included 42 age- and gender-matched 
subjects randomly selected among patients referred to 
an endocrinological and internist outpatient clinic (1:1 
ratio), with no personal history or clinical suspicion of 
any pituitary disease. ACRO patients were divided into 
two groups at the last follow-up: 1) patients in biochemi-
cal remission (R-ACRO) presenting normal IGF-1 lev-
els for age and sex without any medical treatment; 2) 
patients with active disease (A-ACRO), who still needed 
medical treatments. In the latter group, we further 
divided controlled A-ACRO patients presenting IGF-1 
levels within the age and sex reference range (cA-ACRO) 
from uncontrolled A-ACRO who displayed still elevated 
IGF-1 levels despite medical therapy (uA-ACRO).
Demographic data, comorbidities, medications, and 
anthropometric measures were collected for each patient 
of both groups. For the ACRO group only, information 
about IGF-1 levels (expressed as % IGF-1 of the upper 
limit of the normal  range for age, ULN), disease activity 
at last follow-up, previous and present acromegaly treat-
ment, pituitary adenoma characteristics at diagnosis were 
gathered from clinical records. Cognitive function was 
assessed by using the age- and education-adjusted mini-
mental state examination (MMSE) test [25]. Functional 
status was investigated with Lawton’s instrumental activi-
ties of daily living (IADL) scale and with Barthel index for 
basic activities of daily living (BADL), that assess inde-
pendence in daily living activities [26, 27]. Physical per-
formance, mobility skills, and sarcopenia were tested by 
using the Timed Up and Go test (TUG), the Short Physi-
cal Performance Battery (SPPB) and the Handgrip test to 
both hands. Cut-offs established by The European Work-
ing Group on Sarcopenia in Older People (EWGSOP) 
were considered to interpret test results and to define 
sarcopenia presence and severity [28]. Nutritional status 
was determined by The Mini-Nutritional Assessment 
Scale-Short Form (MNA-SF), that screens for malnutri-
tion risk [29]. Geriatric depression scale (GDS-15) by 
Yesavage [30] was used to screen the presence of depres-
sive symptoms, evaluating the degree of depression. The 
SF-36 [31] test was used to investigate the self-reported 
measure of health-related quality of patient life, exploring 
the perception of eight life aspect domains. All tests and 
their interpretation cut-offs are listed in Table  1. They 
were administered by two operators (one per center) 
equally trained in this study protocol.
This study is in accordance with the principles set 
out in the Declaration of Helsinki, has been specifically 
approved by the Local Ethics Committee (Comitato 
Etico Indipendente di Area Vasta Emilia Centro, CE-
AVEC, at the Policlinico S.Orsola-Malpighi in Bologna) 
and authorized by the General Director of the Azienda 
Ospedaliero Universitaria in Ferrara (protocol number 
CE-AVEC 364/2018/Oss/AOUFe). All subjects read and 
signed the informed consent form before enrolling in the 
study.
Statistical analysis
Categorical variables are presented as absolute values/
percentages and Chi-square test was used to compare 
results. Continuous variables are described by mean val-
ues ± standard error of the mean (SE) and were com-
pared by using the Student’s T test in case of a normal 
distribution or by using the Mann–Whitney U test in 
case of non-normal distribution. Normality was tested 
with the Kolmogorov–Smirnov test. Statistical correla-
tion between two continuous variables was evaluated 
by Pearson’s correlation coefficient. P < 0.05 was consid-
ered as statistically significant. A multivariate analysis 
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of variance (MANOVA) was performed to evaluate the 
involvement of comorbidites in the relationship between 
acromegaly and geriatric outcomes.
Results
The mean age in both groups was 73 ± 6 years (range 
65-91) and female gender was the most represented 
(69%). Daily medications number was significantly higher 
in ACRO as compared to CTR (8 ± 3 vs. 3 ± 2), without 
significant differences regarding antidepressant/antipsy-
chotic drugs. BMI was higher in ACRO, but no signifi-
cant differences were found concerning weight, waist and 
hip circumference as compared to CTR (Table 2).
ACRO clinical data at diagnosis and at last follow-up 
are summarized in Table 3.
ACRO, 13 were in remission at the last evaluation 
(R-ACRO) and 29 presented active disease (A-ACRO), all 
controlled by medical therapy except for one patient with 
uncontrolled active disease. Concerning pituitary func-
tion, hypoadrenalism, hypothyroidism, hypogonadism 
and hyperprolactinemia were present in 21, 50, 17 and 
10% of ACRO patients, respectively. Hyperprolactinemia 
was treated with dopamine agonists (DA). Replacement 
therapy was provided to all patients except for 3 hypo-
gonadal male patients due to comorbidities. Cardio- and 
cerebro-vascular diseases, respiratory diseases, metabolic 
impairments, goiter, endocrine dysfunctions, gastroin-
testinal diseases, musculoskeletal complications, and 
bone diseases were significantly more frequent in ACRO 
as compared to CTR (Fig.  1). Regarding endocrine dis-
functions, CTR presented only primary hypothyroidism 
which was well replaced on levothyroxine therapy.
Table 1 Tests employed in the multidimensional evaluation
a As defined in the 2018 EWGSOP guidelines [28]
Dimension assessed Test Cut-off and interpretation References
Cognitive function MMSE ≥ 24: normal
18-23: mild cognitive impairment
11-17: moderate cognitive impairment
< 10: severe cognitive impairment
[25]
Functional status IADL 8 (5 in males): independence
0: total dependence
[27]









TUG <  20 s: normal [28]
SPPB >  8: normal
Handgrip test ≥ 27 (males): normal
≥ 16 (females): normal
Nutritional status MNA-SF > 11: normal
8–11: risk of malnutrition
≤7: malnutrition
[29]
Depression GDS-15 ≤ 5: normal
6-10: minor depression
>  10: major depression
[30]
Quality of life SF-36 100: best own health perception
0: worse own health perception
[31]
Table 2 ACRO and CTR clinical and anthropometric 
characteristics
* P < 0.05
Clinical and anthropometric characteristics ACRO CTR 
Total (n) 42 42
M/F 13/29 13/29
Mean age (years ± SE) 73 ± 0.9 73 ± 0.9
Medications per day (n ± SE) *8 ± 1.2 3 ± 0.5
Antidepressants / antipsychotics / antiepi-
leptic medications (n, %)
11 (26%) 5 (12%)
Weight (Kg ± SE) 79 ± 2.5 74 ± 1.5
BMI (Kg/m2 ± SE) *30 ± 0.9 28 ± 0.6
 ∙  < 18.5 (n, %) 0 (0%) 0 (0%)
 ∙ 18.5-24.99 (n, %) 6 (14%) 10 (23.8%)
 ∙ 25 − 29.99 (n, %) 17 (40%) 22 (52.4%)
 ∙ 30-34.99 (n, %) 10 (24%) 6 (14.3%)
 ∙ 35-39.99 (n, %) 5 (12%) 4 (9,5%)
 ∙ > 40 (n, %) 4 (10%) 0 (0%)
Waist circumference (cm ± SE) 137 ± 6.2 132 ± 6
Hip circumference (cm ± SE) 141 ± 5.7 139 ± 5.9
Waist/Hip circumference ratio 0.97 ± 0.09 0.95 ± 0.09
Page 4 of 9Gagliardi et al. BMC Geriatr          (2021) 21:598 
Cognitive evaluation showed significantly lower MMSE 
scores in ACRO as compared to CTR (Table  4); both 
groups had mean MMSE scores in the normal range. 
Indeed, according to MMSE test cut-off, no differences 
were detected concerning the prevalence of cognitive 
impairment among the two groups. Scores negatively 
correlated with age in ACRO (r = − 0.25, P < 0.01) and 
positively in CTR (r = 0.37, P < 0.01).
Functional assessment demonstrated significantly 
lower IADL and BADL scores in ACRO as compared to 
CTR, without differences in functional dependence lev-
els. In ACRO both scores negatively correlated with age 
(r = − 0.29, P < 0.01; r = − 0.41, P < 0.01). On the contrary, 
in CTR age positively correlated with IADL (r = 0.07, 
P < 0.01) and negatively with BADL (r = − 0.29, P < 0.01).
Regarding physical performance status and sarcopenia, 
ACRO obtained poorer results at TUG and SPPB tests as 
compared to CTR (Table 4). No difference was observed 
at the handgrip test and the strength developed by both 
hands did not differ between the two groups. In ACRO 
age negatively correlated with both SPPB test (r = − 0.37, 
P < 0.01) and handgrip test (dominant hand r = − 0.29 
and non-dominant hand r = − 0.21, P < 0.01). In addition, 
age positively correlated with time to complete the TUG 
test (r = 0.17, P < 0.01). In CTR only a negative correlation 
with the dominant handgrip test was found (r = − 0.18, 
P < 0.01). Nutritional status did not differ between groups 
on the basis of MNA-SF test scores. Scores become worse 
with age in ACRO but not in CTR (r = − 0.30 vs. 0.06, 
P < 0.01). Among ACRO, mean MNA-SF scores were 
significantly lower in R-ACRO than A-ACRO (P < 0.05), 
with a higher number of patients at risk of malnutri-
tion as compared to A-ACRO (69%, P < 0.05). Depres-
sion screening did not reveal any significant differences 
between the groups. GDS-15 scores did not show any 
correlation with age in both groups. All evaluations are 
summarized in Table 4.
ACRO presented less satisfactory scores in 5 out of 8 
SF-36 questionnaire domains as compared to CTR: phys-
ical activity, physical pain, general health, vitality, social 
activities (Fig.  2). Correlation with age was negative in 
all 8 fields in ACRO (P < 0.05). On the contrary, in CTR 
this correlation was significantly positive in the general 
health, vitality, and mental health fields. The multivari-
ate analysis showed the significant association of specific 
comorbidities with geriatric outcome scores in ACRO 
(Table  5). No differences were observed comparing 
R-ACRO and A-ACRO in all items, except for MNA-SF 
scores.
Discussion
Our study demonstrates an increased frailty of older 
acromegaly patients as compared to non-acromegaly 
older patients, especially concerning cognitive function, 
functional status, and physical performance, with conse-
quent negative impact on their quality of life.
In our study the ACRO group presented an average age 
of 58 ± 10 years at diagnosis. A third of them had been 
diagnosed after 65 years of age, possibly supporting the 
hypothesis that acromegaly has a mild clinical phenotype 
in the elderly patient [17]. Two thirds were diagnosed 
before 65 years of age, therefore we cannot exclude an 
influence of disease duration on our results. Indeed, it is 
well consolidated that disease duration influences comor-
bidities development and worsening [1]. ACRO group 
was predominantly represented by females, in agreement 
with recent Italian series [18, 22, 23, 32]. Pituitary adeno-
mas were mostly macroadenomas, in contrast with lit-
erature data reporting that older patients generally carry 
smaller tumors as compared to younger patients [17]. 
Table 3 ACRO clinical data
RT conventional radiotherapy, GK gamma knife radiotherapy, SSA somatostatin 
analogue, PEG pegvisomant, DA dopamine agonists
a Available in 33 out of 42 patients (9 patients were under Pegvisomant 
treatment)
DIAGNOSIS
 Mean age (years ± SE) 58 ± 1.5
 Age ≥ 65 (n, %) 13 (31%)
 Age ≤ 65 (n, %) 29 (69%)
 Microadenoma (n, %) 16 (38%)
 Macroadenoma (n, %) 26 (62%)
 Extra-sellar extension (n, %) 12 (29%)
LAST FOLLOW-UP
 Remission (n, %) 13 (31%)
 Active controlled disease (n, %) 28 (67%)
 Active uncontrolled disease (n, %) 1 (2%)
 Mean % IGF-1 ULN ± SE -29 ± 4.5%
 Mean GH levels (ng/ml ± SE)a 0.98 ± 0.1
Ongoing acromegaly therapy
 ∙ None (n, %) 13 (31%)
 ∙ SSA (n, %) 15 (35.7%)
 ∙ PEG (n, %) 2 (4.7%)
 ∙ DA (n, %) 1 (2.4%)
 ∙ PEG + DA (n, %) 1 (2.4%)
 ∙ SSA + DA (n, %) 4 (9.5%)
 ∙ SSA + PEG (n, %) 5 (11.9%)
 ∙ SSA + PEG + DA (n, %) 1 (2.4%)
Previous acromegaly treatment
 ∙ Surgery (n, %) 29 (69%)
 ∙ RT (n, %) 1 (2%)
 ∙ GK (n, %) 2 (5%)
 ∙ SSA (n, %) 14 (33%)
 ∙ PEG (n, %) 4 (10%)
 ∙ DA (n, %) 2 (5%)
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This difference was further underlined by the finding 
that macroadenomas were more represented than micro-
adenomas when considering only patients diagnosed 
with acromegaly after 65 years old. Therefore, our data 
indicate that age at diagnosis is not always predictive of 
tumor size. However, all macroadenomas were enclosed 
in the sellar space, in keeping with previous series [17] 
suggesting a milder behaviour of these tumors.
Our study shows a significant difference in BMI 
between ACRO and CTR, but waist/hip circumference 
ratio does not differ in the two groups, suggesting a simi-
lar fat tissue distribution. However, the available data do 
not allow to confirm this hypothesis and further studies 
are needed.
Most patients presented an active disease but con-
trolled by medical treatment, mostly somatostatin ana-
logs (SSA), in line with the guidelines [33]. Therefore, our 
ACRO group was homogeneous in terms of biochemical 
disease control, allowing us to hypothesize that the worse 
performance of ACRO vs. CTR was not due to aging nor 
to poor disease control, but possibly to the consequences 
of GH/IGF-1 excess before treatment. These data are in 
line with previous reports, showing that cognitive and 
psychological performance does not improve in acro-
megaly patients over time despite disease control [4, 
9, 34, 35].
ACRO presented a more complex clinical picture than 
CTR, as indicated by the significantly higher number 
of medications per day and the more frequent comor-
bidities. Both acromegaly and aging are associated to 
comorbidities development, but our data suggest that 
acromegaly disease might be an additional factor nega-
tively influencing older adults health. We observed a 
more important involvement of the musculoskeletal 
system in ACRO than in CTR. Indeed, arthropathy and 
osteoporosis are often described since the diagnosis 
of acromegaly and they usually persist also after remis-
sion [16, 36–38]. Such evidence might partially explain 
our results derived from physical and functional evalu-
ations. Indeed, ACRO obtained worse scores in the 
TUG and SPPB tests, describing worse physical perfor-
mance and mobility skills. On the contrary, handgrip 
test results were similar in ACRO and CTR, in keeping 
with Füchtbauer et  al. who did not find proximal mus-
cle weakness in patients normalized after acromegaly 
remission. We also found that bone and musculoskeletal 
diseases are independently associated with geriatric out-
come scores in ACRO. Our results are in agreement with 
the study by da Silva Homem et al., who found a greater 
risk of falls and a worse performance concerning balance 
control, and peripheral muscle function in 17 acromeg-
alic older adults (age range: 63-73 years) compared with 
20 paired controls [15]. Furthermore, we demonstrated 
that scores related to physical performance, mobility 
skills and sarcopenia worsen with age, suggesting a syn-
ergistic effect between aging and acromegaly, accounting 
for an increased frailty in older acromegaly patients. This 
hypothesis is further strengthened by the evidence that 
3 out of 42 ACRO patients had been unable to complete 
the tests evaluating physical performance. Contrary to 
our findings, Hatipoglu et al. found no difference between 
the ACRO and CTR aging groups, by performing 2 out 
Fig. 1 ACRO and CTR comorbidities. CCVD = cardio/cerebro-vascular disease (arrhythmia, hypertension, valvulopaties, ischemic heart disease, 
cerebral aneurysm, stroke); Resp = respiratory (OSAS); Neuro = neurological; Metabolic = metabolic impairments (diabetes mellitus, dyslipidemia); 
ED = endocrine dysfunctions (hypothyroidism, hypogonadism, hypoadrenalism, hyperprolactinemia); Onco = oncological; GI = digestive system 
diseases (intestinal polyposis, gastritis, hepatic steatosis, cholelithiasis, diverticulosis); MS = musculoskeletal diseases; Bone = bone diseases 
(osteopenia/osteoporosis). *P < 0.05 ACRO vs. CTR 
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of 3 tests among those we employed. These differences 
may be due to the different number of evaluated patients; 
in addition, comorbidities were not fully characterized 
[2]. Furthermore, evidence regarding the relationship 
between acromegaly, sarcopenia and musculoskeletal sta-
tus is still conflicting and very few data are available in 
the elderly, impairing the evaluation of the role of quanti-
tative and qualitative muscle dysfunction [17].
Our study shows that functional status assessed by 
IADL and BADL is worse in ACRO vs. CTR, similarly 
to what found by Hatipoglu et  al. [2]. Furthermore, in 
ACRO aging was negatively correlated with performance 
in instrumental and basic daily activities, possibly due 
to the worse musculoskeletal system condition and the 
presence of other comorbidities, as shown by the mul-
tivariate analysis. Our data support the hypothesis that 
musculoskeletal impairment is the primary source of 
physical pain and disability with negative impact on daily 
social activities. On the other hand, the employed evalu-
ation was unable to discriminate the degree of depend-
ence, in keeping with Fatti et al. [16] and suggesting that 
other tools are necessary to better identify those patients 
who need more assistance.
Cognitive dysfunction in acromegaly ranges from 2 to 
33% of patients and is mostly represented by memory 
and attention impairments. Neurocognitive alterations 
persist after surgical remission [4] suggesting that hor-
monal disease control is not sufficient to restore cognitive 
functions [34]. In keeping with these data, our experience 
shows that also in ACRO older patients cognitive perfor-
mance is significantly impaired, despite disease control, 
worsening with age. Similarly to what found for func-
tional status, MMSE was unable to capture the degree of 
cognitive impairment, probably due to the reduced size 
of our sample. Our data suggest that investigating cogni-
tive function is appropriate, especially in older patients, 
considering MMSE scores as a preliminary evaluation.
Regarding nutritional and psychological evaluation, 
ACRO and CTR were similar in our settings. Hatipoglu 
et  al., instead, described a worse nutritional status with 
a greater risk of malnutrition in acromegaly compared to 
the general older population, independently of GH/IGF-1 
levels or disease activity [2]. These results suggest that 
MNA-SF and GDS-15 tests may not be sensitive enough 
to detect nutritional and psychological differences in 
controlled acromegaly versus normal aging subject. Fur-
ther studies with larger cohorts and more sensitive tools 
are desirable.
Previous studies have widely documented the asso-
ciation between acromegaly and a poor QoL [6, 35, 39]. 
We found that QoL is worse in 5 out of 8 domains of the 
SF-36 questionnaire, confirming that acromegaly nega-
tively impacts QoL also in the aging patient. AcroQoL, a 
disease-specific QoL questionnaire [40], is not applicable 
in our settings since it cannot measure QoL in CTR.
Finally, no relevant differences were found between 
A-ACRO and R-ACRO, but definitive conclusions can-
not be derived due to the restricted number of the 
subsamples.
The multicenter design of our study allowed us to col-
lect a consistent number of older acromegaly patients, 
considering that acromegaly is a rare disease. However, 
the main limitation of our study still remains the small 
Table 4 ACRO and CTR multidimensional evaluation
* P < 0.05 ACRO vs. CTR 
Multidimensional evaluation ACRO CTR 
MMSE
 Score ± SE *26 ± 0.8 28 ± 0.3
 Normal (n, %) 35 (83.3%) 41 (98%)
 Mild cognitive impairment (n, %) 5 (11.9%) 1 (2%)
 Moderate cognitive impairment (n, %) 1 (2.4%) 0 (0%)
 Severe cognitive impairment (n, %) 1 (2.4%) 0 (0%)
IADL
 Score ± SE *5 ± 0.3 7 ± 0.2
 Total independence (n, %) 20 (48%) 29 (69%)
 Total dependence (n, %) 0 (0%) 0 (0%)
BADL
 Score ± SE *88 ± 3.5 99 ± 0.3
 Total independence (n, %) 27 (64.3%) 37 (88.1%)
 Slight dependence (n, %) 4 (9.5%) 2 (4.8%)
 Moderate dependence (n, %) 7 (16.6%) 3 (7.1%)
 Severe dependence (n, %) 2 (4.7%) 0 (0%)
 Total dependence (n, %) 2 (4.7%) 0 (0%)
TUG 
 Seconds ± SE *16 ± 1.1 11 ± 0.8
 Sarcopenia (n, %) *14 (36%) 2 (5%)
SPPB
 Score ± SE *7 ± 0.5 10 ± 0.3
 Sarcopenia (n, %) *28 (70%) 6 (15%)
HANDGRIP TEST
 Dominant hand (Kg ± SE) 22 ± 1.6 24 ± 3.9
 Non dominant hand (Kg ± SE) 17 ± 1.6 20 ± 1.2
 Sarcopenia (n, %) 14 (36%) 9 (21%)
MNA-SF
 Score ± SE 11 ± 0.3 12 ± 0.3
 Normal (n, %) 22 (52%) 29 (69%)
 Malnutrition risk (n, %) 18 (43%) 13 (31%)
 Malnutrition (n, %) 2 (5%) 0 (0%)
GDS-15
 Score ± SE 5 ± 0.5 4 ± 0.5
 Normal (n, %) 24 (57%) 30 (71%)
 Minor depression (n, %) 16 (38%) 12 (29%)
 Major depression (n, %) 2 (5%) 0 (0%)
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samples size which might reduce the statistical power 
of our analysis. Two operators (one per center) equally 
trained in this study protocol have tested patients and 
controls in the two centers, making results more homo-
geneous. The multidimensional geriatric assessment of 
our study consists of simple tools readily available in rou-
tine clinical practice and extensively used in the geriatric 
general population. However, even if we derived signifi-
cant conclusions from their applications, all tests did not 
perform equally in the acromegaly population. From our 
experience, the TUG and SPPB tests should be consid-
ered as useful tools to evaluate performance and sarcope-
nia status in acromegalic patients during routine clinical 
practice. They are easy to carry out and they are time and 
cost saving. However, body composition should also be 
explored besides patient performance, with specific tools 
(e.g. BIA, DEXA, MRI or CT).
Conclusions
Our multidimensional evaluation suggests that older 
acromegaly patients are much frailer than the general 
geriatric population, with a negative impact on their 
daily quality of life, supporting the indication to submit 
acromegaly patients to geriatric evaluation at an earlier 
age as compared to the general population. Our results 
suggest that disease management should take care also 
of such typical geriatric issues that could appear earlier 
and more importantly in acromegaly. Older acromegaly 
patients may indeed need assistance and support in 
their daily activities more often.
Therefore, it seems advisable to include physical, 
functional, cognitive, nutritional and psychological sta-
tus assessments in routine clinical practice. However, 
other studies are needed to identify the most appropri-
ate and efficient geriatric tools for acromegaly disease 
evaluation.
Fig. 2 ACRO and CTR SF-36 questionnaire. PA = physical activity; PL = physical limitations; PP = physical pain; GH = general health; V = vitality; 
SF = social functioning; EL = emotional limitations; MH = mental health. * P < 0.05
Table 5 Comorbidities associated to geriatric outcome scores in ACRO by multivariate analysis
* P < 0.05
IADL BADL TUG SPPB
Cardio and cerebrovascular disease OR (IC 95%) 1.89* (1.17 - 3.03) 1.23 (0.77 - 1.98) 0.83 (0.51 - 1.33) 0.99 (0.62 - 1.59)
Respiratory disease OR (IC 95%) 0.39* (0.24 - 0.62) 0.60* (0.37 - 0.96) 1.91* (1.19 - 3.06) 0.54* (0.34 - 0.88)
Metabolic impairment OR (IC 95%) 0.95 (0.59 -1.53) 1.08 (0.67 - 1.74) 0.60 (0.38 – 0.97) 1.40 (0.87 - 2.25)
Goitre OR (IC 95%) 0.87 (0.54 - 1.40) 0.78 (0.49 - 1.26) 0.90 (0.56 - 1.44) 0.74 (0.46 - 1.19)
Endocrine dysfunctions OR (IC 95%) 1.19 (0.74 - 1.91) 0.34* (0.21 - 0.54) 0.63* (0.39 - 1.01) 1.05 (0.65 - 1.69)
Oncological disease OR (IC 95%) 1.43 (0.89 - 2.30) 1.23 (0.77 - 1.98) 0.85 (0.53 - 1.36) 1.43 (0.89 - 2.30)
Digestive diseases OR (IC 95%) 0.86* (0.54 - 1.39) 0.85* (0.53 - 1.37) 1.52* (0.95 - 2.45) 0.69* (0.43 - 1.10)
Psychiatric OR (IC 95%) 0.49 (0.31 - 0.79) 0.48 (0.30 – 0.77) 1.08 (0.67 - 1.74) 0.84 (0.52 - 1.34)
Musculoskeletal diseases OR (IC 95%) 0.89 (0.55 - 1.42) 0.89 (0.56 - 1.44) 1.73* (1.08 - 2.78) 0.89 (0.55 - 1.42)
Bone diseases OR (IC 95%) 1.03* (0.64 - 1.65) 1.36* (0.85 - 2.19) 1.11* (0.69 - 1.79) 0.67* (0.42 – 1.08)
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